Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 25 Oct 2017 Trial design presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
- 01 May 2017 Status changed from not yet recruiting to recruiting.
- 13 Dec 2016 New trial record